Johnson & Johnson Q3 Earnings Top Estimates; Lifts FY21 View Above Market
Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company’s quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10. In the third quarter, […]
Read more